Predictive Significance of the Alterations of p16INK4A, p14ARF, p53, and Proliferating Cell Nuclear Antigen Expression in the Progression of Cervical Cancer
Open Access
- 1 April 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (7) , 2407-2414
- https://doi.org/10.1158/1078-0432.ccr-03-0242
Abstract
Purpose: The purpose of this research was to evaluate the clinical significance of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen (PCNA) expression in tumor progression of cervical cancer. Design: Seventeen patients (40 samples) with consecutive cervical lesions from normal squamous epithelium, inflammation of the cervix to cervical intraepithelial neoplasm (CIN) and invasive cervical squamous cell cancer (SCC), or from CIN to SCC were collected for this study. Expression of p16INK4A, p14ARF, p53, and PCNA were detected by immunohistochemistry on paraffin-embedded sections. Human papillomavirus DNA was detected simultaneously with PCR and typed according to its DNA sequence. Results: p16INK4A overexpression was significantly higher in CIN (75%) and in SCC (75%) than in normal or inflammation of the cervix (12.5%; P < 0.01, P < 0.05, respectively). The positive rate of p14ARF expression was higher in SCC (83%) than in normal/inflammation of the cervix (25%; P < 0.05). PCNA expression was negative in normal or inflammation of the cervix, but an increased in expression was seen in 63.2% in CIN and 100% in SCC (P < 0.01, P < 0.05). When the time interval for disease progression from initial biopsy to CIN 3 or invasive cancer was compared with states of p16INK4A expression, cases stained positive for p16INK4A progressed within 64.2 months as compared with 122.3 months among those stained negatively (P < 0.01). Cases with increased p14ARF expression also had a short time interval for disease progression of 78.8 months as compared with 108.3 months in cases that were p14ARF negative. Cases with stable or decreased p53 expression had the shortest time interval for progression of 32.3 months in contrast to cases with no p53 expression (113.9 months). However, cases with increasing p53 expression progressed within 60.8 months. Conclusions: Our results suggested that altered states of p16INK4A, p14ARF, p53, and PCNA may be valuable markers to predict the progression of cervical neoplasia.Keywords
This publication has 33 references indexed in Scilit:
- Translational approaches to improving cervical screeningNature Reviews Cancer, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- p16INK4a Immunohistochemistry Improves Interobserver Agreement in the Diagnosis of Cervical Intraepithelial NeoplasiaThe American Journal of Surgical Pathology, 2002
- Telomerase activity, MIB‐1, PCNA, HPV 16 and p53 as diagnostic markers for cervical intraepithelial neoplasiaNoteAPMIS, 2001
- Immunolocalization of Human p14ARF to the Granular Component of the Interphase NucleolusExperimental Cell Research, 2000
- The Possible Role of p53 and bcl-2 Expression in Cervical Carcinomas and Their Premalignant LesionsGynecologic Oncology, 2000
- Type-Specific Persistence of Human Papillomavirus DNA before the Development of Invasive Cervical CancerNew England Journal of Medicine, 1999
- An Immunohistochemical Analysis of Heat Shock Protein 70, p53, and Estrogen Receptor Status in Carcinoma of the Uterine CervixGynecologic Oncology, 1999
- The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasiaSeminars in Cancer Biology, 1996
- p53, guardian of the genomeNature, 1992